SRCSGT | 65 | The Pacific Region 12; Southwest Regions 9/10; Heartland Region 5 and Mid-Atlantic Region 2 announce a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Intravenous Solutions.

FBO DAILY ISSUE OF JUNE 24, 2009 FBO #2767
SOURCES SOUGHT

65 -- The Pacific Region 12; Southwest Regions 9/10; Heartland Region 5 and Mid-Atlantic Region 2 announce a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Intravenous Solutions.

Notice Date: 6/22/2009
Notice Type: Sources Sought
NAICS: 423450 — Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
Contracting Office: Department of the Army, U.S. Army Medical Command, Pacific Regional Contr Ofc TAMC, Pacific Regional Contr Ofc TAMC, ATTN: MCAA PC BLDG 160, 160 Krukowski Road, Honolulu, HI 96859-5000
ZIP Code: 96859-5000
Solicitation Number: W81K02-09-T-3021
Response Due: 7/13/2009
Archive Date: 9/11/2009
Point of Contact: Mary L. Summers, 8084333686<br />
E-Mail Address: Pacific Regional Contr Ofc TAMC
(mary.summers1@us.army.mil)
Small Business Set-Aside: N/A
Description: The primary objective of this program is to standardize the quality of care across the regions based on the critical balance of clinical efficacy and value. It is intended for this initiative to result in the standardization of a clinically preferred product and source at the best possible price. It is also intended that standardized products be obtained through the Department of Defense Prime Vendor Program. As a clinically driven program, vendors and products must meet specific technical criteria plus products must meet or exceed specific clinical performance expectations as a primary consideration. Among vendors who meet the technical criteria and the products meet or exceed the clinical performance expectations, price will become the deciding factor in the selection. The major Medical Treatment Facilities (MTFs) in the Pacific Region, TRBO Region 12 area include but are not limited to Tripler Army Medical Center, U.S. Naval Hospital Okinawa, U.S. Naval Hospital Guam, U.S. Naval Hospital Yokosuka, MEDDAC-K Seoul, 374th Medical Group Yokota Air Base, 18th Medical Group Kadena Air Base. The major Medical Treatment Facilities in the Southwest Region, TRBO Region 9/10 area include the Naval Medical Center San Diego; David Grant Medical Center Travis Air Force Base, Naval Hospital Camp Pendleton, Robert E. Bush Hospital Twenty-Nine Palms, Weed Army Community Hospital Fort Irwin, Naval Hospital Lemoore, 9th Medical Group Beale Air Force Base, 30th Medical Group Vandenberg Air Force Base, the 61st Medical Squadron Los Angeles Air Force Base, and the 95th Medical Group Edwards Air Force Base. The major Medical Treatment Facilities in the Mid-Atlantic Region, TRBO Region 2 area include the Womack Army Medical Center, FT Bragg; 43rd Medical Group, Pope Air Force Base; Naval Medical Center Portsmouth; Naval Hospital Camp Lejeune. The major Medical Treatment Facilities in the Heartland Region, TRBO Region 5 area include Wright Patterson Air Force Base Ohio, Scott Air Force Base Illinois, Naval Health Clinics of Great Lakes Illinois, Blanchfield Army Community Hospital Ft Campbell Kentucky, Ireland Army Community Hospital Ft Knox, Kentucky, Naval Hospital Corps School Great Lakes Illinois, and USCG Air Station Traverse City, Michigan. This standardization action is part of the Medical/Surgical Prime Vendor program executed by the Defense Supply Center Philadelphia (DSCP), Directorate of Medical Materiel. In order to participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the Prime Vendors for the program. This is pursuant to the DAPA clause by which DAPA holders agree to the standardization process and to allow Prime Vendors to distribute their products. This RFRIAQ is a supplement to the Prime Vendor Program and is not a contract. For additional information regarding DSCPs Prime vendor program please access their web site at https://dmmonline.dscp.dla.mil The resulting Regional Incentive Agreement (RIA) will be for a base period of two years (24 months) from date of selection with three one-year (12 months) option periods. Anticipated selection date is Oct 2009. Products and vendors that pass the technical criteria and pass the clinical performance expectations will be considered clinically preferred products and sources. Among these clinically preferred products and sources price will be the determining factor for this initiative. The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of MTF clinical preference and product availability. Point of Contact: Mary Summers, TRBO Technical Director 808-433-3686, mary.summers1@us.army.mil Cheryl Janus, RN, TRBO Clinical Analyst 808-433-7985, cheryl.janus@amedd.army.mil B. Products & Performance Required. The Pacific, Southwest, Mid-Atlantic and Heartland Regions are seeking product line items in the category of Intravenous Solutions, which at a minimum, includes the high volume lines below. Within these regions, this product line has an estimated annual dollar requirement of $1,201,088. This forecast is based on historical prime vendor sales during a recent 12-month period. The top 10 high volume usage lines for this project include: #2B2324X, SOLUTION IV LACTATED RINGERS 1000ml, 23331 Del Qty, $289,833.79 #2B1324X, SOLUTION IV SODIUM CHLORIDE 0.9% 1000ml, 16908 Del Qty, $172,048.31 #2B1323Q, SOLUTION IV SODIUM CHLORIDE 0.9% 500ml, 6527 Del Qty, $99,113.64 #L8000, SOLUTION IV SODIUM CHLORIDE 0.9% 1000ml, 9224 Del Qty, $73,694.60 #L7500, SOLUTION IV LACTATED RINGERS 1000ml, 7607 Del Qty, $67,785.10 #2B2323Q, SOLUTION IV LACTATED RINGERS 500ml, 2756 Del Qty, $60,765.21 #2B1322Q, SOLUTION IV SODIUM CHLORIDE 0.9% 250ml, 1393 Del Qty, $39,466.77 #2B1301, SOLUTION IV SODIUM CHLORIDE 0.9% 50ml, 374 Del Qty, $39,069.81 #2B1302, SOLUTION IV SODIUM CHLORIDE 0.9% 100ml, 364 Del Qty, $37,946.64 #L8001, SOLUTION IV SODIUM CHLORIDE 0.9% 500ml, 1341 Del Qty, $20,354.47 At the request of the Pacific, Southwest, Mid-Atlantic and Heartland Regional MTFs, vendors will provide conversion information, prime vendor order numbers, and itemization of the brands, types, and packaging information of the products supplied by the vendor. C. Instructions to Vendors Vendors interested in participating in this standardization initiative should email their (1) Company name and address, (2) Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address) to mary.summers1@us.army.mil and cheryl.janus@amedd.army.mil. and (3) Identification of the RFQRIA to which the vendor is responding. Submissions must be received by 5:00 post meridiem (p.m.) Hawaii Standard Time (HST) on the specified closing date/time of this solicitation. Vendors that fail to meet this submittal deadline will be disqualified from participating. In a one step notification process, the Pacific Region TRBO will request responses to the technical/company criteria, no charge literature, no charge sample sets, and best available pricing from each interested vendor. Vendors will have 30 calendar days to 1.) respond to the Pacific Region TRBO with their responses to the technical/company criteria and submission of best value price quotes; and 2.) deliver no charge literature and no charge sample sets to all participating MTFs. No charge literature and no charge samples must be received by the participating MTFs by close of business (COB) 5:00 PM HST, 30 days after the date of request to supply samples. All vendors must send the Pacific TRBO verification regarding the date of shipment. Vendor responses to the technical criteria must be in a prescribed electronic spreadsheet format that will be provided by the Pacific Region TRBO. Best value pricing must be in a prescribed electronic spreadsheet format, based upon the total requirements of the Pacific, Southwest, Mid-Atlantic and Heartland Regions. Vendors that fail to respond to the technical criteria, fail to provide a price quote or fail to deliver the no charge literature and no charge sample sets within the time prescribed will be disqualified from further consideration. Vendor quotes should contain the vendor's best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendor's best responses to all technical criteria listed in this announcement. Vendor quotes should contain the vendor's best tiered-pricing discounts off of the vendor's DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs of the Pacific, Southwest, Mid-Atlantic, and Heartland Regions). As this process will require vendors to submit certain information electronically, vendors are strongly encouraged to confirm with the Regional POC (stated above) that their electronic submissions have arrived at the Regional TRBO. Vendors are advised to confirm receipt, allowing adequate time for resubmission before the deadline, should a problem have occurred with the first submission. All e-mails must be digitally signed. The no charge samples to be provided are as follows: Intravenous Solutions - One (1) each of: Lactated Ringers 1000 ml; 0.9% NaCl 1000 ml; Dextrose/Saline 5%-0.45% 1000 ml; 5% Dextrose in Lactated Ringers 1000 ml; Dextrose 5% 1000 ml; 45% NaCL 1000 ml; Sterile Water for Injection 1000 ml; 0.9% NaCl 500 ml; 5% Dextrose 500 ml; Lactated Ringers 500 ml; 0.9% NaCl 250 ml; 0.9% NaCl 100 ml; 5% Dextrose and Water 100 ml; 5% Dextrose and Water 50 ml; 0.9% NaCl 50 ml; 0.9% NaCl 25 ml; Normal Saline 250 ml for use with connectors for adding vials; Normal Saline 100 ml for use with connectors for adding vials; Normal Saline 50 ml for use with connectors for adding vials; 5% Dextrose and Water 250 ml for use with connectors for adding vials; 5% Dextrose and Water 100 ml for use with connectors for adding vials; 5% Dextrose and Water 50 ml for use with connectors for adding vials. Vial connectors and ad-mixture devices one (1) each. Vendors that do not meet the deadline to deliver the literature and samples by the required deadline will be disqualified from further consideration in this standardization initiative The no charge literature and no charge sample sets are required to be shipped to the following: Region Pacific TRBO Region 12 Tripler Army Medical Center ATTN: Capt D. ONeill & George Fitzgerald TPRB Evaluation Samples Logistics Division, Materiel Branch Bldg 161 Krukowski Road Honolulu, Hawaii 96859-5000 (808) 433-5718 US Naval Hospital Okinawa Japan TPRB Evaluation Samples Attn: LT Shane Knisley, MSC, USN & LTJG D. Salinas Bldg 6000, Camp Lester Chatan-Cho, Nakagami-Gun, Okinawa, Japan 904-0103 011-81-611-743-7815 US Naval Hospital Guam Farenholt Road Bldg 1, Room L103 Attn: LT Robert Morrison, MSC, USN & LCDR Hicks, NC, USN TPRB Evaluation Samples Agana Heights, Guam 96910 671-344-9671 Region Southwest TRBO Region 9/10 Robert E. Bush Hospital Main Operating Room TPRB Evaluation Samples Box 788250 MCAGCC Twenty-nine Palms, CA 92278-8250 ATTN: LCDR Mark Anderson Phone: (760) 830-2313 Tri-Service Regional Business Office Southwest Region TPRB Evaluation Samples 34800 Bob Wilson Dr., Suite 110 San Diego, CA 92134 ATTN: Cindy Ingrao, RN, MSN Phone: (619) 532-8517 Naval Hospital Camp Pendleton TPRB Evaluation Samples Bldg 100 Main Operating Room Camp Pendleton, CA 92055-5191 ATTN: CDR Loretta Howerton Phone: 760-725-1871 David Grant Medical Center ATTN: 1LT Suzanne Lewis TPRB Evaluation Samples 101 Bodin Circle, Bldg 777 Medical Logistics Warehouse Travis AFB, CA 94535 707-423-5280 Region Mid-Atlantic TRBO Region #2 Womack Army Medical Center, FT Bragg, NC Womack Army Medical Center ATTN: MAJ Shane Crask TPRB Evaluation Samples CSS 2817 Reilly Road Fort Bragg, NC 28310 (910) 907-7287 43rd Medical Group, Pope AFB, NC Attn: TSgt Katherine Scott TPRB Evaluation Samples 43rd MDG/SGSL 383 Maynard Street Pope AFB, NC 28308 910-394-4646 Naval Medical Center Portsmouth, Portsmouth, VA ATTN: CDR Karen Ecarius TPRB Evaluation Samples Naval Medical Center Portsmouth Portsmouth, VA 23708 757-953-3294 Naval Hospital Camp Lejeune, Camp Lejeune, NC ATTN: LT James Driscoll TPRB Evaluation Samples Naval Hospital Camp Lejeune 100 Brewster Blvd Camp Lejeune, NC 28547 910-450-4876 Region Heartland TRBO Region #5 Wright Patterson Air Force Base Med Center ATTN: Capt Majella Brown, TSgt Leigh Taylor, Capt Julie Meek, Ms Peggy Ross TPRB Evaluation Samples 4881 Sugar Maple Dr. Bldg 830 Wright-Patterson AFB, OH 45433 937-257-3524 Blanchfield Army Community Hospital ATTN: 1st LT Marissa Bernadette TPRB Evaluation Samples Bldg 650 b, Level 1 1 Joel Dr Ft Campbell, KY 42223 270-798-8203 The Regions intend to evaluate quotes and select a vendor or vendor(s), on initial submission/quotes. The regions intend to evaluate quotes and select a vendor or vendors, on initial submission/quote, without discussion. However, the Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. The Region reserves the right to reject all quotes and cancel the RFQRIA if it is determined to be in the governments best interest. Price will be analyzed based on the vendors anticipated Post Standardization Costs. Post standardization costs will be calculated for each vendor by applying the vendors offered prices to the anticipated annual usage of the region. Unmatched items will be represented in the Post Standardization Cost at the current suppliers non-discounted price. Among the products and sources that are determined to be clinically preferred, the best price (Post Standardization Cost) will be the deciding factor. Source Selection Procedures The Tri-Service Product Review Boards (TPRBs) for the Pacific, Southwest, Mid-Atlantic and Heartland Regions are the governing bodies of the standardization process and program. These boards include clinicians and logisticians from the MTFs within the Pacific, Southwest, Mid- Atlantic and Heartland Regions. The boards are chaired by the Designated Senior Logisticians (DSLs). They are the deciding officials for this initiative. The Pacific Region TPRB is Co-Chaired by a physician from Naval Hospital Yokosuka and an Air Force Nurse Corps officer assigned to the Hawaii Multi-Service Marketing Management Office (MSMMO). The DSLs are the deciding officials for this initiative. Technical Criteria Evaluations The vendors responses to the technical criteria will be reviewed for acceptability. Acceptability is defined as follows: 1) based on the vendors responses, the evaluators have reasonable confidence that the vendor can meet the standard of each technical criterion; 2.) based on the vendors responses, the evaluators have reasonable confidence that the line of products and/or services submitted meet the medical standards of care of the community that are applicable to such products or services; and 3) the information provided by the vendor is factually correct. Any misrepresentation of information will disqualify the vendor from further consideration. Failure to provide any requested information will disqualify the vendor from further consideration. Vendors must achieve an acceptable rating on their responses to the technical criteria for continued consideration in this initiative. Vendors who do not achieve an acceptable rating will be disqualified. Technical Criteria 1. Vendors must provide a complete product line of Intravenous Solutions. A complete product line includes all usage items for the Military Treatment Facilities (MTFs) during a recent 12 month period. Usage items are DAPA items ordered at least once per month and at least one unit per order. For this initiative a complete product line includes the following products: Lactated Ringers 1000 ml; 0.9% NaCl 1000 ml; Dextrose/Saline 5%-0.45% 1000 ml; 5% Dextrose in Lactated Ringers 1000 ml; Dextrose 5% 1000 ml; 45% NaCL 1000 ml; Sterile Water for Injection 1000 ml; 0.9% NaCl 500 ml; 5% Dextrose 500 ml; Lactated Ringers 500 ml; 0.9% NaCl 250 ml; 0.9% NaCl 100 ml; 5% Dextrose and Water 100 ml; 5% Dextrose and Water 50 ml; 0.9% NaCl 50 ml; 0.9% NaCl 25 ml; Normal Saline 250 ml for use with connectors for adding vials; Normal Saline 100 ml for use with connectors for adding vials; Normal Saline 50 ml for use with connectors for adding vials; 5% Dextrose and Water 250 ml for use with connectors for adding vials; 5% Dextrose and Water 100 ml for use with connectors for adding vials; 5% Dextrose and Water 50 ml for use with connectors for adding vials. Vial connectors and ad-mixture devices one (1) each to be included. Vendors are required to supply all listed items. 2. Vendors must provide a complete list of the Intravenous Solutions available from the vendor, along with product literature to the TRBO as a First Response to the RFQ. The MTFs must receive the literature along with the samples when requested in response to this RFQRIA. 3. Vendors must have a DAPA or be in the process of applying for a DAPA number for the Intravenous Solutions product line. Provide the DAPA number or proof of the application process in response to this RFQRIA. 4. Vendors must have a separate agreement with the current Prime Vendor for the Heartland and Mid Atlantic Regions, Owens & Minor, and a separate agreement with the current Prime Vendor for the Pacific and Southwest Region Prime Vendor, Cardinal Healthcare. 5. Vendors must submit discounts off DAPA for all products included in this standardization initiative. Vendors that fail to submit a discount from DAPA will be disqualified. Where lower uncommitted FSS prices are available, DAPA holders are required by previous agreement to provide the uncommitted FSS price as the DAPA price. Vendors shall not quote uncommitted FSS prices as the discounted price for purposes of this standardization initiative. 6.Vendors products must be manufactured in an ISO certified facility. Vendors must provide a statement confirming that their products are manufactured in an ISO certified facility in response to this RFQRIA. 7. Vendors response to this RFQRIA must confirm that their product line is totally latex free. 8. Vendors products and/or product packaging must be clearly labeled as latex free. In response to this RFQRIA Vendors must state where on the products and/or packaging the latex free declaration is located, i.e. on each IV bag or on the container. 9. Vendors are required to provide documentation regarding the presence of PVC/ DHEP (Di 2-ethylhexyl phthalate) in the IV/Fluids bags. The presence or absence of PVC/DHEP is not a dis-qualifier; however, the failure to disclose the presence of PVC/DHEP in response to the Technical Criteria, will result in disqualification from this standardization effort. 10. Vendors must provide the empirical studies/data on any product which contains any amount of DEHP/PVC. Full disclosure is required as to the origin of the studies, i.e. research sponsored by their company versus FDA or FDA CDRH studies. Failure to disclose these studies, in response to the Technical Criteria request, will result in disqualification from this standardization effort. 11. Vendors must use only non-toxic, color fast dyes in the labeling process. 12. Vendors must provide, in response to the Technical Criteria request, documentation specifying the type of medication-additive port on the Intravenous Solutions container (for example needle-access; needleless-access). This is for informational purposes as requested by the Clinical Pharmacists on the TPRB CPTs. 13. Vendors must provide, in response to the Technical Criteria request, documentation specifying that their solutions do not change physical composition or chemical deterioration with temperature changes of greater than 30 degrees ambient room temperature or less than 30 degrees ambient room temperature. 14. Vendors must provide, in response to the Technical Criteria request, documentation specifying all safety alerts issued by any governmental or accreditation agencies regarding the safety of your IV Fluids. Include any adverse outcomes reported to your company regarding the use of your IV Fluids. Vendors with unresolved safety alerts and/or unresolved adverse outcome reports will be disqualified. 15. Vendors must have a Return Goods Policy, and must provide an electronic copy of the policy with the vendors response to Technical Criteria request. 16. Vendor must provide information on the ports and types of vial connectors that are compatible with each type of port on the Intravenous Solution bags. Vendors must provide this information in response to the Technical Criteria request. 17. Vendor must provide information on the sizes of medication vials which are compatible with the sizes of the ports for the Intravenous Solution bags. Vendors must provide this information in response to the Technical Criteria request. 18. Vendor must provide instructional materials on the use and activation of their respective connector systems/devices. Vendors must provide this information in response to the Technical Criteria request. 19. Vendor must provide instructional materials for use of their respective connector systems/devices when used in the sterile laminar flow hood. Vendors must provide this information in response to the Technical Criteria request. 20. Vendor must identify whether or not they use a fluid barrier overwrap for their respective IV Solutions. Vendors must provide this information in response to the Technical Criteria request. 21. Vendor must provide information in response to the Technical Criteria request on the expiration/stability of the IV Solution bag once overwrap is removed. Clinical Performance Evaluation: Specific Clinical Product Teams (CPTs), which consist of physicians, nurses, allied health professionals, and technicians from the participating MTFs, will evaluate the clinical performance of product samples based on the evaluation criteria below. Each criterion is of equal weight. Products will be scored on a pass/fail basis. Products must meet or exceed the performance expectation contained in each outlined clinical performance criterion to receive a score of pass. Products that receive a score of pass from 80% of the participating clinicians will be considered clinically preferred products and will continue to the pricing analysis phase of this standardization initiative. Vendors whose products fail to receive a score of pass from 80% of the participating clinicians will be disqualified from further consideration. In the event that the identical product is offered by multiple vendors, the regions reserve the right to limit the evaluation to one sample of the duplicative products. Clinical evaluations will be conducted in a non-clinical (non-patient) setting. The clinical performance criteria for this initiative are: Clinical/Performance Criteria: 1.Type of fluid solution is easily identified from the outer packaging and fluid solution container. 2.The fluid container is optically clear, making it easy to determine the condition of the fluid. (Addresses Patient Safety any sediment, particle threads, opaque quality of the fluid, or foreign materials can be acutely and potentially deadly to a patient the solution is considered contaminated) 3.Container labeling is easy to read and includes volume gradient and expiration date. 4.The fluid container access port can be easily spiked with the tubing remaining secure with no leaking. 5. The fluid container access port is easily spiked by the connector systems/devices, by Pharmacy clinicians, for drug ad-mixtures or medication vial therapies.
Web Link: FBO.gov Permalink
(https://www.fbo.gov/spg/USA/MEDCOM/DADA16/W81K02-09-T-3021/listing.html)
Place of Performance: Address: Pacific Regional Contr Ofc TAMC ATTN: MCAA PC BLDG 160, 160 Krukowski Road Honolulu HI<br />; Zip Code: 96859-5000<br />
Record: SN01851777-W 20090624/090622235054-4cbe802d6f667ed0308b546583ee9101 (fbodaily.com)
Source: FedBizOpps Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's FBO Daily Index Page |

Loren Data's SAM Daily™

65 -- The Pacific Region 12; Southwest Regions 9/10; Heartland Region 5 and Mid-Atlantic Region 2 announce a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Intravenous Solutions.